Please Scroll Down to See Forums Below
Best Anti Estrogen , I want all answers
- Thread starter benrock
- Start date
Hey stockked why don't you edit out the names in post #12.
Nolvadex doesnt reduce estrogen it simply blocks the receptor. Anastrozole, letrozole and aromasin actually prevent the creation of estrogen via the P450 enzyme and greatly reduce its presense. Nolva isnt even in the same catagory but works if protection is all you care about.HULKSTER said:
stockked said:SORRY BRO!
Just protecting everybody's best interests...
H
HULKSTER
Guest
Dial_tone said:
Based on doing 30mg ed Dbol cycles, as well as 40mg ed Anavar cycle, which anti-e would work best for me? Nolvadex or Letrozole?
Negative effect on Lipid Profile
I have posted this article before. Arimidex also negatively affects the lipid profile. Aromasin is by far the safest and most effective antiestrogen.
Effect of letrozole on the lipid profile in postmenopausal women with breast cancer.
Eur J Cancer 2001 Aug;37(12):1510-3 (ISSN: 0959-8049)
Elisaf MS; Bairaktari ET; Nicolaides C; Kakaidi B; Tzallas CS; Katsaraki A; Pavlidis NA
Department of Internal Medicine, Medical School, University of Ioannina, GR 451 10 Ioannina, Greece. [email protected].
Hormonal therapy plays a central role in the overall treatment of breast cancer. Aromatase inhibitors can inhibit the aromatase enzyme system resulting in a reduction of oestrogens. Letrozole is a non-steroidal aromatase inhibitor that effectively blocks aromatase activity without interfering with adrenal steroid biosynthesis. The drug can significantly reduce the levels of plasma oestrogens, which remain suppressed throughout the treatment. Data are scarce concerning the influence of these drugs on serum lipid levels. In the present study, we evaluated the effects of letrozole on the serum lipid profile in postmenopausal women with breast cancer. A total of 20 patients with breast cancer were treated with letrozole, 2.5 mg once daily. After an overnight fast, serum lipid parameters (total cholesterol, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol, triglycerides, apolipoproteins A1, B and E and lipoprotein (a)) were measured before treatment and at 8 and 16 weeks afterwards. A significant increase in total cholesterol (P=0.05), LDL cholesterol (P<0.01) and apolipoprotein B levels (P=0.05) in the serum, as well as in the atherogenic risk ratios total cholesterol/HDL cholesterol (P<0.005) and LDL cholesterol/HDL cholesterol (P<0.005) was noticed after letrozole treatment. We conclude that letrozole administration in postmenopausal women with breast cancer has an unfavourable effect on the serum lipid profile.
I have posted this article before. Arimidex also negatively affects the lipid profile. Aromasin is by far the safest and most effective antiestrogen.
Effect of letrozole on the lipid profile in postmenopausal women with breast cancer.
Eur J Cancer 2001 Aug;37(12):1510-3 (ISSN: 0959-8049)
Elisaf MS; Bairaktari ET; Nicolaides C; Kakaidi B; Tzallas CS; Katsaraki A; Pavlidis NA
Department of Internal Medicine, Medical School, University of Ioannina, GR 451 10 Ioannina, Greece. [email protected].
Hormonal therapy plays a central role in the overall treatment of breast cancer. Aromatase inhibitors can inhibit the aromatase enzyme system resulting in a reduction of oestrogens. Letrozole is a non-steroidal aromatase inhibitor that effectively blocks aromatase activity without interfering with adrenal steroid biosynthesis. The drug can significantly reduce the levels of plasma oestrogens, which remain suppressed throughout the treatment. Data are scarce concerning the influence of these drugs on serum lipid levels. In the present study, we evaluated the effects of letrozole on the serum lipid profile in postmenopausal women with breast cancer. A total of 20 patients with breast cancer were treated with letrozole, 2.5 mg once daily. After an overnight fast, serum lipid parameters (total cholesterol, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol, triglycerides, apolipoproteins A1, B and E and lipoprotein (a)) were measured before treatment and at 8 and 16 weeks afterwards. A significant increase in total cholesterol (P=0.05), LDL cholesterol (P<0.01) and apolipoprotein B levels (P=0.05) in the serum, as well as in the atherogenic risk ratios total cholesterol/HDL cholesterol (P<0.005) and LDL cholesterol/HDL cholesterol (P<0.005) was noticed after letrozole treatment. We conclude that letrozole administration in postmenopausal women with breast cancer has an unfavourable effect on the serum lipid profile.
